Emma Children's Hospital, Amsterdam UMC, Pediatric Oncology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Expert Rev Anticancer Ther. 2021 Jul;21(7):765-780. doi: 10.1080/14737140.2021.1895756. Epub 2021 Mar 29.
: Survival rates of pediatric acute myeloid leukemia (AML) in low- and middle-income countries (LMICs) seem extremely poor, and the available literature on the matter is scarce. Accordingly, there is a limited understanding of poor treatment outcomes seen in this population.: We provide an overview of the available literature with respect to treatment outcomes of pediatric AML in LMICs yielding poor outcomes compared to high-income countries. Moreover, treatment outcomes vary markedly between LMICs. In addition, there is a wide variation among studies in how treatment outcomes are reported and analyzed.: The substantially inferior treatment outcomes of pediatric AML in LMICs emphasize the unprecedented importance of global initiatives and international collaborations to improve the survival of these patients. A coordinated approach is necessary to carry out country-specific situational analyses. These analyses will result in operational plans on how to structurally implement childhood cancer registries, align healthcare infrastructure, build on capacities, and provide universal health coverage in LMICs. In addition, we strongly recommend that, in the future, LMICs document, analyze, and publish pediatric AML treatment outcomes in a more structured and uniform manner.
儿童急性髓系白血病（AML）在低收入和中等收入国家（LMICs）的生存率似乎极低，相关可用文献也十分匮乏。因此，对于这一人群中所见的不良治疗结局，我们的了解十分有限。
我们就治疗结局方面的现有文献进行了综述，这些文献涉及与高收入国家相比，LMICs 中儿童 AML 的治疗结局较差的情况。此外，LMICs 之间的治疗结局差异显著。此外，研究中报告和分析治疗结局的方式也存在很大差异。
与高收入国家相比，LMICs 中儿童 AML 的治疗结局明显较差，这凸显了全球倡议和国际合作对于改善这些患者生存的前所未有的重要性。需要采取协调一致的方法开展特定国家的情况分析。这些分析将产生关于如何在 LMICs 中结构性地实施儿童癌症登记处、调整医疗保健基础设施、建立能力以及提供全民健康覆盖的业务计划。此外，我们强烈建议，未来 LMICs 应更有组织和统一地记录、分析和发布儿童 AML 治疗结局。
